The Effect of 5-Reductase Inhibitors on Erectile Function

The document from April 17, 2008, reviewed the impact of 5α-reductase inhibitors (5ARIs) like finasteride and dutasteride on erectile function. It discussed various studies, including animal models and clinical trials, to assess the effects of these drugs, which are used to treat conditions like benign prostatic hyperplasia and male pattern hair loss. The review found that reported rates of erectile dysfunction (ED) in men using 5ARIs varied widely, with some studies showing no significant effect and others reporting higher incidences of ED, which could be influenced by a placebo effect. Long-term studies indicated that the incidence of ED might decrease over time. The document concluded that while 5ARIs significantly reduce serum dihydrotestosterone (DHT) levels, the incidence of ED is relatively low and tends to diminish over time, and that testosterone is likely more critical for erectile function than DHT. Further research was suggested to better understand ejaculation disorders related to 5ARIs and the role of androgens in erectile physiology.